|
|
Post by gerald on Mar 2, 2018 14:48:34 GMT -5
This treatment basically involves taking liquid nitrogen and flash freezing parts of the lungs, which kills the tissue. The lung will then grow back but it regenerates withotu the inflamation that causes the problem. This tests involved 35 people so that is encouraging. It treats a single lobe in this trial. Unfortunately it does not say How much of the surface is treated. How severe the COPD is at the time of treatment. How much of an improvement was obtained. How painful was the procedure. ------------------------------------------ CSA Medical Announces the Completion of Treatments in the RejuvenAir Safety and Feasibility Study for patients with Chronic Bronchitis LEXINGTON, Mass., March 1, 2018 /PRNewswire/ -- CSA Medical, Inc. announced the completion of the treatment phase for its ongoing study The Safety and Feasibility Study of RejuvenAir for Treating Chronic Bronchitis Patients (NCT02483637). This prospective, open label, single arm study of COPD patients with known chronic bronchitis is being conducted at three sites in The Netherlands, United Kingdom, and Canada. The study strongly supports the feasibility of using Liquid Nitrogen Metered Cryospray™ (MCS) throughout the central airways to ablate inflamed bronchial epithelium allowing non-inflamed tissue to regenerate after treatment. The final patient treatment was completed at the University Medical Center Groningen, The Netherlands by Dr. Dirk-Jan Slebos, M.D., PhD of the Department of Pulmonary Diseases, who reported that "The Liquid Nitrogen Metered Cryospray therapy is very well tolerated by our patients and appears to have a beneficial response with a decrease in their cough and mucus production as well as an improvement in breathing, resulting in increased physical activity." Professor Pallav Shah, M.D., FRCP from the Royal Brompton, London, further notes, "The ability to deliver a highly tolerable treatment with such a remarkable safety profile means that Liquid Nitrogen Metered Cryospray has the potential to quickly change the course of the disease for the millions of people who suffer from chronic bronchitis." The 35 patient study completed treatment without device related adverse events. "The ability to deliver Liquid Nitrogen MCS treatments in a bronchoscopy suite without issues speaks to the procedure's safety," stated Ellen Sheets, M.D., CEO at CSA Medical. "Additionally, early data on treatment response from patient reported outcome instruments remains strongly positive, supporting RejuvenAir as a potential procedure for patients suffering from chronic bronchitis." About Chronic Bronchitis Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD). Bronchitis is inflammation of the bronchial airways. A chronic bronchitis diagnosis is defined by cough with productive sputum of three months duration for two consecutive years. www.prnewswire.com/news-releases/csa-medical-announces-the-completion-of-treatments-in-the-rejuvenair-safety-and-feasibility-study-for-patients-with-chronic-bronchitis-300606899.htmlclinicaltrials.gov/ct2/show/NCT02483637 |
|
|
|
Post by lavishgail on Mar 2, 2018 18:00:17 GMT -5
WOW, thank you so much for putting this up Gerald very interesting.
|
|
|
|
Post by gerald on Mar 2, 2018 21:49:58 GMT -5
This is the first reference I have seen specifically for Chronic bronchitis. It is good to see some R&D finally being done in this area.
|
|
|
|
Post by lavishgail on Mar 2, 2018 23:01:47 GMT -5
Yes indeed fascinating it's about time.
|
|
|
|
Post by peg on Mar 9, 2018 20:14:48 GMT -5
That is fantastic news. I see that is done in the United States, does anyone know if Canada is doing the trials as well?
|
|
|
|
Post by gerald on Mar 10, 2018 0:25:40 GMT -5
Peg, I have not seen it in Canada yet. It first showed up in Europe about 2 years ago.
I was surprised to see it was in testing in the US on such a large group. The success rate in teh US will depend on when/if it shows up here
|
|
